In the context of the potential immunomodulatory properties of curcumin in counteracting the detrimental effects of concurrent exposure to Deoxynivalenol (DON) and Aflatoxin B1 (AFB1), a comprehensive 28-days trial was conducted utilizing 60 randomly allocated mice divided into four groups. Administration of curcumin at a dosage of 5 mg/kg body weight in conjunction with DON at 0.1 mg/kg and AFB1at 0.01 mg/kg body weight was undertaken to assess its efficacy. Results indicated that curcumin intervention demonstrated mitigation of splenic structural damage, augmentation of serum immunoglobulin A (IgA) and immunoglobulin G (IgG) levels, elevation in T lymphocyte subset levels, and enhancement in the mRNA expression levels of pro-inflammatory cytokines TNF-α, IFN-γ, IL-2, and IL-6. Furthermore, curcumin exhibited a suppressive effect on apoptosis in mice, as evidenced by decreased activity of caspase-3 and caspase-9, reduced expression levels of pro-apoptotic markers Bax and Cytochrome-c (Cyt-c) at both the protein and mRNA levels, and the maintenance of a balanced expression ratio of mitochondrial apoptotic regulators Bax and Bcl-2. Collectively, these findings offer novel insights into the therapeutic promise of curcumin in mitigating immunosuppression and apoptotic events triggered by mycotoxin co-exposure.
文章引用产品列表
-
- F2100401
- 流式抗体(新品), 流式抗体
Anti-Mouse CD4, FITC (Clone:GK1.5)流式抗体 (新品)
- ¥208.00 – ¥440.00
-
- F2100402
- 流式抗体(新品), 流式抗体
Anti-Mouse CD4, PE (Clone:GK1.5)流式抗体 (新品)
- ¥160.00 – ¥264.00
-
- F21004A02
- 流式抗体(新品), 流式抗体
Anti-Mouse CD4 (RM4-5),PE 流式抗体 (新品)
- ¥128.00 – ¥264.00
-
- F21008A02
- 流式抗体(新品), 流式抗体
Anti-Mouse CD8α, PE (Clone:2.43) 流式抗体 (新品)
- ¥208.00 – ¥440.00
-
- F2100802
- 流式抗体(新品), 流式抗体
Anti-Mouse CD8α (Clone:53-6.7), PE 流式抗体 (新品)
- ¥208.00 – ¥440.00